VG Med IF b79818-03L kidneys bilateral masses extensive mesenteric adenopathy T cell leukemia lymphoma CT kidneys bilateral masses extensive mesenteric adenopathy T cell leukemia lymphoma CT 51F abdominal pain T cell leukemia lymphoma metastases CT

<
<

Ashley Davidoff MD

51-year-old female abdominal pain
 

Part A — Questions

Q1. Major finding(s) visible in the image (select all that apply):




Additional Information
see below

2. Findings


Bilateral Solid Renal Masses 
Left Pleural Effusion
Left Renal Cyst
Hepatic Cysts

Caption T-Cell Lymphoma with Bilateral Renal Involvement
A CT scan of a 51-year-old female reveals multiple solid masses involving both kidneys (green arrowheads) and a single simple cyst in the left kidney (yellow asterisk) . A small left pleural effusion is also present (pink asterisk) . Additionally, there are multiple known simple cysts within the liver  (white asterisk).
The bilateral, solid renal masses are highly characteristic of secondary renal lymphoma (metastases). The presence of a pleural effusion further supports the diagnosis of a widespread systemic disease. The liver cysts are noted as benign and incidental findings, unrelated to the patient’s primary malignancy.
In the context of a known diagnosis of T-cell leukemia/lymphoma, these findings are consistent with advanced-stage, extranodal disease. The kidneys are a common site for hematologic spread in aggressive lymphomas.
Courtesy Ashley Davidoff, MD | TheCommonVein.net (b79818-03aL)

Part A: Answers Table
Q1. Major finding(s)
1 ☑Decreased left cortical enhancement
2 ☑ Bilateral solid renal masses
3 ☑ 4 ☒ Solid liver masses

 

Part B: Radiological Findings Table

Finding Definition Comment
Solid Renal Mass • A kidney lesion in which at least 25% of its volume enhances by at least 20 Hounsfield units after intravenous contrast. • A solid renal mass is generally considered malignant until proven otherwise. (Silverman, S.G., et al. Radiology. 2019)
Cystic Renal Mass • A simple benign cyst is a round, thin-walled, homogeneous fluid-filled lesion (0-20 HU) without septa or calcifications. • The Bosniak classification is used to categorize cystic masses from benign (Bosniak I) to malignant (Bosniak IV). (Silverman, S.G., et al. Radiology. 2019)
Asymmetrical Cortical Enhancement • A visible difference in the degree or timing of contrast enhancement between the right and left renal cortices. • This suggests mild functional impairment of the left kidney, likely from mass effect on the left renal vein.
(Kawashima, Radiographics 2000)

Delayed Function of the Left Kidney
In this case, while the timing of the cortical enhancement phase is symmetric, the left kidney’s cortex is visibly less dense (hypoenhancing) compared to the right. This subtle finding is suggestive of impaired venous outflow. When the left renal vein is compressed or impinged upon by adjacent tumor masses, the pressure within the vein increases. This elevated venous pressure is transmitted back to the small vessels and glomeruli of the kidney, leading to increased filtration pressure. This “back-pressure” can slightly delay the washout of contrast material, resulting in a lower peak enhancement during the cortical phase. This finding indicates a mild, early functional compromise of the left kidney due to the mass effect from the lymphoma. (Kawashima, A., et al. Radiographics. 2000)

 

Differential Diagnosis: Multiple Bilateral Solid Renal Lesions

 

Category Condition Key Features
Malignant malignancy Metastases • The most common cause in adults. • Primary cancers often include lung, breast, and melanoma.
  Lymphoma / Leukemia • Common site for extranodal (outside the lymph nodes) disease. • Can present as multiple nodules or diffuse infiltration.
  Multifocal Renal Cell Carcinoma (RCC) • Strong suspicion for a hereditary cancer syndrome (e.g., von Hippel-Lindau disease). • Less common than solitary RCC.
Benign 😇 Angiomyolipomas (AMLs) • Composed of vessels, muscle, and fat. • Multiple and bilateral AMLs are strongly associated with Tuberous Sclerosis Complex.
  Oncocytomas • Benign epithelial tumors. • Multiple and bilateral presentation (oncocytomatosis) is very rare.
Inflammatory & Other inflamed Infection (Abscesses) • Occurs in severe infections like sepsis or pyelonephritis. • Often appear as complex, thick-walled lesions and are associated with clinical signs of infection.
  Infarcts • Areas of dead tissue from lack of blood supply. • Often appear as wedge-shaped solid defects in the kidney.

Other Images from this patient 

Massive Mesenteric Lymphadenopathy with Sandwich Sign
Systemic Lymphoma: The “Sandwich Sign”
Axial CT images (a, c) with magnified views (b, d) demonstrate extensive and massive mesenteric adenopathy (white asterisks) and retroperitoneal lymphadenopathy (white arrowheads). Despite the bulk of the disease, the mesenteric blood vessels are encased by the soft tissue mass without significant occlusion, creating the classic “sandwich sign.” Associated findings include bilateral solid renal masses (green arrowheads), ascites (yellow asterisks), and a benign hepatic cyst.
The disproportionately mild compression of vascular structures by such a large tumor volume is a key feature highly suggestive of lymphoma. The tumor’s characteristically soft and pliable consistency, often described pathologically as “fish flesh,” allows it to envelop structures rather than aggressively constricting them.
The constellation of massive mesenteric and retroperitoneal disease, the “sandwich sign,” discrete renal masses, and ascites confirms widespread systemic involvement. This presentation is highly characteristic of an advanced-stage, aggressive lymphoma.
Courtesy: Ashley Davidoff, MD | TheCommonVein.com (b79818-02b01Lb)

Cardiac Nodule T-Cell Lymphoma
Breat Thickening Pleural Effusion
Ascites

Cardiac T-Cell Lymphoma
Axial CT through the heart of a 51-year-old female who presented with palpitations and known history of T cell Lymphoma. The dominant finding is a nodule in the free wall of the left ventricle (LV) (magnified b red arrowhead). Associated findings include skin thickening of the right breast(white arrowhead), a small left pleural effusion (orange arrowhead), ascites, (yellow arrowhead) and multiple simple cysts in the liver.
Synthesizing the clinical presentation of palpitations with the imaging findings of a nodule in the heart abnormal right breast, and serous effusions (pleural and peritoneal) makes a diagnosis of cardiac lymphoma, specifically T-cell lymphoma, highly probable. The simple liver cysts are noted as incidental findings.
Courtesy Ashley Davidoff, MD | TheCommonVein.net (b79818-00L)

Related Links

Google ImagesGoogleYouTubeWikipediaRadiopediaRadiographicsPubMedChatGPTOpenEvidence

3. Diagnosis


Definition
  • T-cell leukemia/lymphomas are a heterogeneous group of rare and often aggressive malignancies arising from mature (post-thymic) T-lymphocytes.
  • They represent less than 15% of all non-Hodgkin lymphomas (NHL) in the United States.
  • These malignancies can be classified as indolent (slow-growing) or aggressive (fast-growing).
  • Depending on the primary site of involvement, they are categorized as leukemic, nodal, extranodal, or cutaneous.
  • The term “peripheral T-cell lymphoma” (PTCL) is used to describe a diverse group of these lymphomas that arise in lymphoid tissues outside the bone marrow, such as lymph nodes, spleen, skin, and the gastrointestinal tract.
  • Adult T-cell leukemia/lymphoma (ATLL) is a specific, often aggressive subtype caused by the Human T-cell lymphotropic virus type 1 (HTLV-1).
  • Swerdlow SH, et al. Blood. 2016.
Cause
  • The exact etiology of most T-cell lymphomas is unknown, but it involves genetic mutations in T-lymphocytes leading to uncontrolled proliferation.
  • Several risk factors are associated with their development, including viral infections such as HTLV-1 (a known cause of ATLL), Epstein-Barr virus (EBV), and certain autoimmune conditions like celiac disease.
  • Other risk factors include advanced age, male gender, a family history of lymphoma, immunosuppression (e.g., post-organ transplant), and exposure to certain chemicals.
  • Gout O, et al. J Cancer Res Clin Oncol. 2012.
Pathophysiology
  • The pathogenesis of T-cell lymphomas involves the malignant transformation of mature T-cells, which are a critical component of the adaptive immune system.
  • In HTLV-1-associated ATLL, the virus integrates into the host T-cell genome.
  • Viral proteins, such as Tax and HBZ, dysregulate cellular pathways, promoting cell survival, proliferation, and evasion of the host immune response.
  • This leads to genomic instability and the accumulation of genetic and epigenetic alterations over decades, eventually resulting in malignant transformation.
  • The pathophysiology of other PTCLs involves the deregulation of T-cell signaling pathways that control their development and maturation, as well as remodeling of the tumor microenvironment.
  • The specific functional characteristics of the T-cell of origin (e.g., follicular helper T-cells in Angioimmunoblastic T-cell lymphoma) often dictate the clinical and pathological features of the disease.
  • Matsuoka M, et al. Nat Rev Cancer. 2007.
Structural Result
  • At a macroscopic level, T-cell lymphoma leads to the formation of tumor masses and infiltrates in various organs.
  • In this case, the findings include bilateral renal masses and extensive mesenteric adenopathy.
  • Renal involvement typically occurs via lymphomatous infiltration of the interstitium, which can lead to the formation of single or multiple masses that preserve the overall renal contour but disrupt the normal parenchyma.
  • Mesenteric adenopathy results from the malignant proliferation of lymphocytes within the mesenteric lymph nodes, causing them to become enlarged.
  • Histopathologically, the architecture of the involved lymph nodes and extranodal tissues is effaced by a proliferation of malignant T-lymphocytes.
  • Goff L, et al. Hematol Oncol Clin North Am. 2010.
Functional Impact
  • Systemically, T-cell lymphoma can cause B symptoms, including fever, night sweats, and weight loss.
  • The functional impact is organ-specific.
  • Lymphomatous infiltration of the kidneys can cause acute renal failure due to parenchymal destruction, hypercalcemia, or compression of the ureters or renal vasculature.
  • Extensive mesenteric adenopathy can lead to abdominal pain, but often does not cause significant vascular compression due to a lack of desmoplastic reaction.
  • Malignant T-cells can also infiltrate the bone marrow, suppressing normal hematopoiesis, and invade other organs like the liver and spleen, leading to hepatosplenomegaly and organ dysfunction.
  • A compromised immune system is common, leading to opportunistic infections.
  • Tsukasaki K, et al. Chemotherapy. 2012.
Imaging
  • CT: In cases of renal involvement, contrast-enhanced CT typically demonstrates homogeneous, hypovascular masses that show less enhancement than the surrounding renal cortex.
  • In the mesentery, lymphoma presents as enlarged, homogeneous, and mildly enhancing lymph nodes; a characteristic “sandwich sign” can be seen where confluent nodes encase mesenteric vessels.
  • CT is also crucial for staging by detecting visceral organ involvement, such as in the lungs, liver, and bone marrow.
  • PET/CT: FDG-PET/CT is highly valuable for initial staging, assessing treatment response, and detecting occult disease.
  • T-cell lymphomas are typically FDG-avid.
  • PET/CT can reveal the full extent of nodal and extranodal disease, including involvement in the bone marrow, skin, and gastrointestinal tract, and has been shown to be superior to conventional imaging for lesion detection and staging.
  • Juweid ME, et al. J Clin Oncol. 2007.
Labs
  • A definitive diagnosis requires a tissue biopsy (lymph node or extranodal site) with histopathology, immunophenotyping, and molecular studies.
  • Immunophenotyping via flow cytometry or immunohistochemistry is used to confirm T-cell lineage (e.g., expression of CD3, CD2, CD5, CD7) and classify the subtype.
  • A complete blood count (CBC) may show leukocytosis with abnormal lymphoblasts, cytopenias, or eosinophilia.
  • A comprehensive metabolic panel may reveal elevated lactate dehydrogenase (LDH), hypercalcemia, and abnormal renal or liver function tests, which have prognostic significance.
  • Serology for HTLV-1 is essential if ATLL is suspected.
  • A bone marrow biopsy is often performed to assess for involvement.
  • Vega F, et al. Mod Pathol. 2022.
Treatment
  • Treatment for T-cell lymphoma is complex and depends on the specific subtype, stage, and patient factors.
  • For most aggressive PTCLs, the standard first-line therapy is a multi-agent chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOEP (CHOP plus etoposide).
  • For CD30-expressing lymphomas, including anaplastic large cell lymphoma (ALCL), the addition of brentuximab vedotin to chemotherapy has improved outcomes.
  • Due to high relapse rates, consolidation with high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is often recommended for eligible patients in their first remission.
  • In the relapsed or refractory setting, options include several FDA-approved single agents, clinical trials, or allogeneic stem cell transplantation.
  • For aggressive ATLL, first-line treatment is typically an antiviral regimen or chemotherapy.
  • Horwitz S, et al. J Natl Compr Canc Netw. 2019.
Prognosis
  • The prognosis for T-cell lymphomas is generally poorer than for B-cell lymphomas and varies significantly by subtype.
  • Aggressive subtypes such as PTCL-NOS have a 5-year overall survival rate of around 37%.
  • Angioimmunoblastic T-cell lymphoma (AITL) has a 5-year survival rate of about 43%, while for adult T-cell leukemia/lymphoma (ATLL), it can be as low as 20% in aggressive forms.
  • Without treatment, median survival for aggressive forms can be as short as 6-12 months.
  • Prognostic factors for aggressive ATLL include advanced stage, poor performance status, older age, high LDH levels, and hypercalcemia.
  • Even with treatment, relapses are common.
  • Indolent subtypes, such as mycosis fungoides, have a much better prognosis, with 5-year survival rates exceeding 90%.
  • Gallamini A, et al. J Clin Oncol. 2004.

Related Links

Google ImagesGoogleYouTubeWikipediaRadiopediaRadiographicsPubMedChatGPTOpenEvidence

4. Medical History and Culture


A Glimpse into the History and Culture of T-cell Leukemia/Lymphoma

This report delves into the historical, cultural, and educational facets of T-cell Leukemia/Lymphoma, a complex and heterogeneous group of malignancies. The information presented is intended for a medical professional audience, providing context beyond the clinical and radiological findings.

Etymology
  • The term “leukemia” originates from the Greek words leukos (white) and haima (blood), a name coined by the German pathologist Rudolf Virchow in the 1850s to describe the “white blood” appearance in patients with an overabundance of white blood cells.
  • “Lymphoma” is derived from “lymph-“, indicating an origin from a lymphocyte, and the Greek suffix “-oma,” meaning “tumor.”
  • The term “T-cell” designates the origin of these malignant lymphocytes from the thymus, a central organ of the immune system.
AKA / Terminology
  • Peripheral T-cell Lymphoma (PTCL): This is a key term for a diverse group of T-cell lymphomas arising from mature (post-thymic) T-cells in lymphoid tissues outside the bone marrow, such as lymph nodes. The term “peripheral” in this context refers to the origin in these secondary lymphoid organs, not the body’s extremities.
  • Adult T-cell Leukemia/Lymphoma (ATLL): A specific, often aggressive, subtype strongly associated with the Human T-cell lymphotropic virus type 1 (HTLV-1).
  • PTCL-NOS (Not Otherwise Specified): Often referred to as a “wastebasket” diagnosis, this category is for T-cell lymphomas that do not fit into other well-defined subtypes, highlighting the group’s heterogeneity.
  • Flower Cells: A descriptive term for the characteristic malignant lymphocytes seen in ATLL, which have distinctive multi-lobulated nuclei resembling a flower.
Historical Notes
  • The history of lymphoma classification is a journey from pure morphology to an integrated immunologic and genetic approach.
  • Early lymphoma descriptions were made by Thomas Hodgkin in 1832.
  • For much of the 20th century, lymphomas were categorized by morphology alone.
  • A significant shift occurred in the 1970s with the recognition of distinct B-cell and T-cell lineages, leading to immunologically based systems like the Kiel classification developed in Europe by Karl Lennert and colleagues. This was a pivotal moment, as it formally separated B-cell and T-cell lymphomas.
  • The discovery of the first human retrovirus, HTLV-1, by the laboratory of Dr. Robert Gallo in 1979-1980 was a landmark event, providing the first definitive viral cause for a human cancer.
  • Concurrently, researchers in Japan, including Professor Kiyoshi Takatsuki, had described Adult T-cell Leukaemia (ATL), which was found to be caused by this same virus.
  • The technology and intellectual framework developed for the discovery of HTLV-1 were foundational for the subsequent rapid identification of HIV.
The Chemotherapy Revolution and Leukemia Prognosis
  • Before the advent of chemotherapy, a diagnosis of acute leukemia was a death sentence, with a median survival of only about 3 months before 1950.
  • 1940s: The modern era of cancer treatment began with the discovery that nitrogen mustard, a derivative of mustard gas from World War I, could shrink tumors. In 1947, Dr. Sidney Farber achieved the first temporary remissions in childhood acute lymphoblastic leukemia (ALL) using the antifolate aminopterin, a precursor to methotrexate.
  • 1960s: The concept of combination chemotherapy was developed, dramatically increasing survivorship. This marked a turning point, moving from single-agent palliation to curative-intent therapy. The five-year survival rate for leukemia in the U.S. was just 14% in the 1960s.
  • 1970s: Chemotherapy became the standard of care. Bone marrow transplantation was introduced for patients who failed drug treatments, and prophylactic radiation to the central nervous system further reduced relapse rates.
  • 1990s-Present: The development of targeted therapies, starting with rituximab for B-cell cancers in the late 1990s and imatinib for CML in the early 2000s, revolutionized treatment again.
  • Impact on Mortality: Due to these advancements, the overall five-year survival rate for leukemia in the U.S. has quadrupled, from 14% to about 67%. For childhood ALL, the change is even more stark, with five-year survival rates soaring from less than 10% before the 1970s to over 90% today.
Cultural or Practice Insights
  • T-cell lymphomas exhibit significant geographical and ethnic variability.
  • ATLL, caused by HTLV-1, is endemic in specific regions like southwestern Japan, the Caribbean basin, and parts of Central and South America.
  • Other subtypes, such as extranodal NK/T-cell lymphoma, are more common in Asia.
  • In North America and Europe, T-cell lymphomas are rare, representing less than 15% of all non-Hodgkin lymphomas.
  • This rarity means that many community oncologists may only see a few cases in their entire career, making specialized centers with expertise crucial for diagnosis and management.
Notable Figures or Contributions
  • Rudolf Virchow (1821-1902): A German pathologist who first used the term “leukemia.”
  •  
  • Thomas Hodgkin (1798-1866): An English physician who first described lymphoma in 1832, leading to the eponym “Hodgkin’s lymphoma.”
  •  
  • Karl Lennert (1921-2012): A German pathologist who was the driving force behind the Kiel classification, which was among the first to systematically separate T-cell from B-cell lymphomas.
  • Robert Gallo (1937-Present): An American biomedical researcher whose lab co-discovered HTLV-1, the first proven human retrovirus to cause cancer, and linked it to ATLL.
  •  
  • Kiyoshi Takatsuki (1930-2015) & colleagues: Japanese researchers who first defined Adult T-cell Leukaemia (ATL) as a distinct clinical entity in Japan before its viral cause was known.
  •  
  • Thomas Loughran, Jr. & Owen A. O’Connor: Contemporary researchers who are leading authorities in T-cell lymphoma, with Loughran known for discovering LGL leukemia and O’Connor for his extensive work in developing new therapies.
  • Famous People with T-Cell Lymphoma/Leukemia
    • Robert Gallo: While not a patient, Dr. Gallo is a famous figure inextricably linked to the disease. He is the renowned American biomedical researcher who co-discovered the human T-cell lymphotropic virus (HTLV-1) in 1980 and proved it was the cause of Adult T-cell Leukemia/Lymphoma (ATLL). His work was a landmark in proving a virus could cause cancer in humans.
    • Zack Snyder’s Daughter, Autumn Snyder: In a tragic and widely publicized case, Autumn Snyder, daughter of the film director Zack Snyder, was diagnosed with a form of T-cell lymphoma. Her death by suicide in 2017, while battling the illness and its side effects, brought significant attention to the disease.
Quotes and/or Teaching Lines
  • “T-cell lymphomas are the great white whales of hematopathology.” – This line emphasizes their rarity, difficulty in classification, and challenges in establishing clonality.
  • “PTCL-NOS has long been recognized as the ‘wastebasket’ diagnosis…” – A common teaching point underscoring the heterogeneity and diagnostic challenge of this category.
  • “In T-cell lymphoma, an algorithmic approach is less useful…more emphasis is placed on the pathologist’s interpretation of a constellation of features.” – This highlights the diagnostic complexity, requiring integration of multiple data points.
  • “It has intensified the experience of living.” – A quote from a patient, reflecting on the profound personal impact of a T-cell lymphoma diagnosis.

Ode to the T-Cell

From thymic halls, a lineage trained,
A cellular guard, its purpose chained.

But deep within, a code goes wrong,
A single T-cell sings a different song.

A leukos tide, a “white blood” stream,
Fulfills Virchow’s ancient, morbid dream.
In lymph’s domain, a swelling mass,
A “tumor,” -oma, come to pass.

In distant isles, a viral guest,
Puts lymphocytes to a fatal test.
Gallo’s find, a retro-key,
Unlocks the curse of ATLL for all to see.

The scope reveals a blossomed foe,
A “flower cell” where cancers grow.
In nodes and kidneys, infiltrates reside,
With nowhere left for health to hide.

A “wastebasket” name, for types unknown,
On varied paths, the seeds are sown.
From Kiel’s design to modern quest,
This rare whale puts experts to the test.
A complex fight, a vexing art,
To heal the cell that’s torn apart.

Related Links

Google ImagesGoogleYouTubeWikipediaRadiopediaRadiographicsPubMedChatGPTOpenEvidence

6. MCQs


Part A — Questions

Question Choices
Q1. Which of the following best describes the oncogenic function of the Human T-cell lymphotropic virus type 1 (HTLV-1) Tax protein in the pathogenesis of Adult T-cell Leukemia/Lymphoma (ATLL)? 1 It serves as a reverse transcriptase, enabling the integration of the viral genome into the host T-cell DNA.
2 It directly binds to and inactivates tumor suppressor proteins like p53 and Rb.
3 It promotes aberrant activation of signaling pathways, such as NF-κB, to drive clonal proliferation and survival of infected T-cells.
4 It functions primarily to induce apoptosis in non-infected T-cells, creating a competitive advantage for malignant cells.
Q2. The definitive diagnosis of T-cell lymphoma involves immunophenotyping to confirm cellular lineage. Which of the following surface markers is the most specific and fundamental indicator of T-cell lineage across all stages of maturation? 1 CD20
2 CD45
3 CD3
4 CD30
Q3. In a patient with aggressive Adult T-cell Leukemia/Lymphoma (ATLL), which of the following findings is an established poor prognostic factor? 1 Eosinophilia
2 Hypercalcemia
3 Normal Lactate Dehydrogenase (LDH) levels
4 Isolated cutaneous involvement
Q4. According to consensus guidelines and historical data, what is the most common first-line therapeutic strategy for a majority of newly diagnosed, aggressive peripheral T-cell lymphomas (PTCLs) in eligible patients? 1 An antiviral regimen consisting of zidovudine and interferon-alpha.
2 A multi-agent chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
3 Pralatrexate as a single-agent therapy.
4 Immediate allogeneic stem cell transplantation.
Q5. On a contrast-enhanced CT scan for a patient with secondary renal involvement by T-cell lymphoma, what is the most common radiographic appearance of the lymphomatous lesions? 1 Hypervascular masses with avid and heterogeneous enhancement.
2 Multiple, well-defined cystic lesions with fluid density.
3 A solitary, large, centrally necrotic and calcified mass.
4 Homogeneous, hypovascular masses demonstrating less enhancement than the adjacent renal cortex.
Q6. When renal lymphoma extends into the perinephric and retroperitoneal space, which characteristic imaging feature on CT helps differentiate it from infiltrative processes like retroperitoneal fibrosis? 1 The lymphomatous tissue typically causes significant stenosis of the encased renal artery.
2 The lymphomatous mass is usually hypervascular, enhancing more avidly than the renal cortex.
3 The lymphomatous tissue tends to lift the aorta and IVC anteriorly without causing a significant desmoplastic reaction or invasion.
4 It is almost always associated with dense, tethering fibrosis and calcification.
Q7. While FDG-PET/CT is superior for staging, which imaging modality offers the best soft-tissue contrast for characterizing the internal architecture and extent of intra-renal lymphomatous infiltration, particularly when iodinated contrast is contraindicated? 1 Ultrasound with microbubble contrast.
2 Non-contrast CT.
3 Magnetic Resonance Imaging (MRI).
4 Technetium-99m DMSA scintigraphy.

Part B — Answers & Explanations

Question Answer Explanation
Q1. Which of the following best describes the oncogenic function of the Human T-cell lymphotropic virus type 1 (HTLV-1) Tax protein in the pathogenesis of Adult T-cell Leukemia/Lymphoma (ATLL)? ☑ 3 — It promotes aberrant activation of signaling pathways, such as NF-κB, to drive clonal proliferation and survival of infected T-cells. The viral oncoprotein Tax constitutively activates the NF-κB pathway.
This activation is a central mechanism for T-cell transformation and immortalization.
Panfil, Cancers (Basel) 2020
  ☒ 1 — It serves as a reverse transcriptase, enabling the integration of the viral genome into the host T-cell DNA. This is the function of the viral pol gene product, not the Tax protein.
  ☒ 2 — It directly binds to and inactivates tumor suppressor proteins like p53 and Rb. While Tax does interfere with tumor suppressors, its core oncogenic function is activating pro-survival pathways.
  ☒ 4 — It functions primarily to induce apoptosis in non-infected T-cells, creating a competitive advantage for malignant cells. Tax promotes the survival and proliferation of the infected cell, not apoptosis of surrounding cells.
Q2. The definitive diagnosis of T-cell lymphoma involves immunophenotyping to confirm cellular lineage. Which of the following surface markers is the most specific and fundamental indicator of T-cell lineage across all stages of maturation? ☑ 3 — CD3 The CD3 complex is part of the T-cell receptor (TCR) and is a defining feature of the T-cell lineage.
Its presence is the most reliable immunohistochemical marker for identifying T-cells in tissue.
Smith-Garvin, Annu Rev Immunol 2009
  ☒ 1 — CD20 CD20 is a classic B-cell marker, used to identify lymphomas of B-cell origin.
  ☒ 2 — CD45 CD45 is a leukocyte common antigen, present on nearly all hematopoietic cells, not just T-cells.
  ☒ 4 — CD30 CD30 is an activation marker expressed on some T-cell lymphomas (like ALCL) but is not a pan-T-cell marker.
Q3. In a patient with aggressive Adult T-cell Leukemia/Lymphoma (ATLL), which of the following findings is an established poor prognostic factor? ☑ 2 — Hypercalcemia Hypercalcemia is a key indicator of poor prognosis in prognostic models for ATLL.
It is associated with aggressive disease, high tumor burden, and extensive bone involvement.
Bimol, Cureus 2022
  ☒ 1 — Eosinophilia Eosinophilia can be present but is not an independent poor prognostic factor in established ATLL risk models.
  ☒ 3 — Normal Lactate Dehydrogenase (LDH) levels High, not normal, LDH levels are associated with a worse prognosis as it reflects high tumor burden.
  ☒ 4 — Isolated cutaneous involvement Widespread disease is a poor prognostic factor; isolated skin involvement may be seen in less aggressive forms.
Q4. According to consensus guidelines and historical data, what is the most common first-line therapeutic strategy for a majority of newly diagnosed, aggressive peripheral T-cell lymphomas (PTCLs) in eligible patients? ☑ 2 — A multi-agent chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). For decades, CHOP or CHOP-like regimens have been the standard first-line treatment for most aggressive PTCL subtypes.
Newer combinations are being studied, but CHOP remains a widely used backbone.
Reimer, Cancers (Basel) 2022
  ☒ 1 — An antiviral regimen consisting of zidovudine and interferon-alpha. This is a specific therapy for HTLV-1-positive ATLL, not for the majority of PTCLs.
  ☒ 3 — Pralatrexate as a single-agent therapy. Pralatrexate is approved for relapsed or refractory PTCL, not as a first-line treatment.
  ☒ 4 — Immediate allogeneic stem cell transplantation. Stem cell transplant is typically reserved for consolidation or for relapsed/refractory disease.
Q5. On a contrast-enhanced CT scan for a patient with secondary renal involvement by T-cell lymphoma, what is the most common radiographic appearance of the lymphomatous lesions? ☑ 4 — Homogeneous, hypovascular masses demonstrating less enhancement than the adjacent renal cortex. Secondary renal lymphoma classically manifests as multiple, bilateral, hypovascular masses.
The lesions enhance poorly compared to the avidly enhancing normal renal parenchyma.
Aloweni, J Taibah Univ Med Sci 2023
  ☒ 1 — Hypervascular masses with avid and heterogeneous enhancement. This appearance is characteristic of clear cell renal cell carcinoma, not lymphoma.
  ☒ 2 — Multiple, well-defined cystic lesions with fluid density. Lymphoma is a solid infiltrative process; cystic lesions are not a typical feature.
  ☒ 3 — A solitary, large, centrally necrotic and calcified mass. Necrosis and calcification are rare in renal lymphoma but can be seen in renal cell carcinoma.
Q6. When renal lymphoma extends into the perinephric and retroperitoneal space, which characteristic imaging feature on CT helps differentiate it from infiltrative processes like retroperitoneal fibrosis? ☑ 3 — The lymphomatous tissue tends to lift the aorta and IVC anteriorly without causing a significant desmoplastic reaction or invasion. Lymphoma typically behaves as a “soft” tumor that displaces or mantles structures without causing the vascular narrowing or intense fibrotic reaction seen in retroperitoneal fibrosis. [9] Lifting of the great vessels is a classic sign. [4]
  ☒ 1 — The lymphomatous tissue typically causes significant stenosis of the encased renal artery. Vascular occlusion or significant stenosis is rare in lymphoma, which tends to encase vessels without invading or constricting them. [5]
  ☒ 2 — The lymphomatous mass is usually hypervascular, enhancing more avidly than the renal cortex. Renal lymphoma is characteristically hypovascular and enhances less than the normal renal cortex. [2]
  ☒ 4 — It is almost always associated with dense, tethering fibrosis and calcification. Calcification is rare in lymphoma, and dense, tethering fibrosis is the hallmark of retroperitoneal fibrosis, not lymphoma. [5]
Q7. While FDG-PET/CT is superior for staging, which imaging modality offers the best soft-tissue contrast for characterizing the internal architecture and extent of intra-renal lymphomatous infiltration, particularly when iodinated contrast is contraindicated? ☑ 3 — Magnetic Resonance Imaging (MRI). MRI provides excellent soft-tissue resolution without using iodinated contrast, making it ideal for characterizing renal masses in patients with renal insufficiency. [8] It can clearly depict the extent of parenchymal infiltration. [5]
  ☒ 1 — Ultrasound with microbubble contrast. Contrast-enhanced ultrasound is useful but is generally considered inferior to MRI for comprehensive characterization and staging of extrarenal disease. [1]
  ☒ 2 — Non-contrast CT. Non-contrast CT has poor soft-tissue contrast and is inferior to contrast-enhanced studies or MRI for characterizing renal masses.
  ☒ 4 — Technetium-99m DMSA scintigraphy. DMSA is a functional renal scan used to assess cortical scarring and differential function; it is not used for tumor characterization.
Additional Information
see below

Related Links

Google ImagesGoogleYouTubeWikipediaRadiopediaRadiographicsPubMedChatGPTOpenEvidence

7. Memory Page


Mnemonic: The Transformation of a T-Cell
This artistic illustration features three figures. The leftmost figure wears a “T shirt,” the central figure has a shirt reading “Healthy T Cell” with a smiley face, and the rightmost figure is a devil with horns, wearing a “Malignant T Cell” shirt and holding kidneys in his hands.
This image is a visual aid to understand the origin and behavior of T-cell malignancies. The devilish figure represents the malignant transformation of a healthy T-cell. Crucially, the devil is holding the kidneys, symbolizing the propensity of this cancer to spread (metastasize) and form solid tumor masses in extranodal sites, with the kidneys being a common target.
This mnemonic visually contrasts a healthy T-cell with its cancerous counterpart and uses the devil holding the kidneys to specifically remember that T-cell leukemia/lymphoma frequently causes masses in the kidneys.
AI-assisted Davidoff Art — Memory Image – TheCommonVein.com (b79818-03aLMADb)

The Malignant T-Cell’s Grasp: A Renal Tale

A simple shirt, a letter plain,
A pun to start within the brain.
Then see the cell, a healthy guide,
With happy face and nothing left to hide.
A guardian of the body’s grace,
Keeping each system in its place.

But watch the change,
the awful turn,
A lesson that we all must learn.
The smile gives way to angry red,
A twisted thought, a rising dread.
The cell that once was pure and good,
Is now completely misunderstood.

Behold the fiend with horns and fire,
Consumed by malignant desire.
With hands prepared, it waits to claim
The kidney’s function, health, and name.
A visual tale of friend to foe,
To help the seeds of knowledge grow.

Related Links

Google ImagesGoogleYouTubeWikipediaRadiopediaRadiographicsPubMedChatGPTOpenEvidence
>
>

1. Challenge

2. Findings

3. Diagnosis

4. Medical History and Culture

6. MCQs

7. Memory Page